TGTX
Tg Therapeutics·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Buy"
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TGTX
Tg Therapeutics, Inc.
A biopharmaceutical company that develops therapeutics for diseases caused by protien or gene dysfunction
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560
--
TG Therapeutics, Inc., was incorporated in Delaware in 1993. The company is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of new therapies for B cell-mediated diseases. Its product BRIUMVI (ublituximab-xiiy) has received regulatory approval in the US, EU and UK for the treatment of adult patients with relapsing multiple sclerosis.
Company Financials
EPS
TGTX has released its 2025 Q3 earnings. EPS was reported at 2.43, versus the expected 0.22, beating expectations. The chart below visualizes how TGTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TGTX has released its 2025 Q3 earnings report, with revenue of 161.71M, reflecting a YoY change of 92.79%, and net profit of 390.89M, showing a YoY change of 9974.61%. The Sankey diagram below clearly presents TGTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
